Plain-English translation of NCT07756580 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called that is being developed to treat deep forehead wrinkles (the lines that appear between your eyebrows when you frown). The study will give participants this new medication first, then follow it two or three weeks later with , which is an already-approved wrinkle treatment. Researchers want to see if using these two treatments together in this sequence is safe and works well.
Forehead wrinkles caused by repeated facial expressions are common, but current treatment options are limited. This trial is exploring whether the new treatment could offer patients better or longer-lasting results, especially when combined with an established therapy.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the new medication on Day 1 at the study site. Depending on which group you are assigned to, you will return two or three weeks later to receive an injection of . You will then be followed by the research team for about 4.5 months total to monitor how safe the treatment is and how well it works for reducing your forehead wrinkles.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
United States